查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951259

mRNA平台市場 - 全球產業規模、佔有率、趨勢、機會及預測（按適應症、易用性、mRNA類型、最終用戶、地區和競爭格局分類，2021-2031年）

mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Usability, By mRNA Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 mRNA 平台市場預計將從 2025 年的 75.2 億美元成長到 2031 年的 95.9 億美元，年複合成長率為 4.14%。

此領域涵蓋利用傳訊RNA指導宿主細胞內特定蛋白質的合成，並透過脂質奈米顆粒等遞送系統實現疾病的預防和治療。推動這一領域發展的關鍵因素包括感染疾病爆發期間對快速疫苗開發平台的迫切需求，以及將該方法拓展至腫瘤學和罕見疾病治療領域的大規模投資。 mRNA藥物聯盟的報告強調了生產的重要性，報告指出，到2025年，49%的受訪行業組織認為生產流程效率是提高全球mRNA藥物可負擔性和可及性的關鍵因素。

市場概覽
預測期 2027-2031
市場規模：2025年 75.2億美元
市場規模：2031年 95.9億美元
複合年成長率：2026-2031年 4.14%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

儘管取得了這些進展，但由於mRNA分子固有的不穩定性，市場仍面臨巨大的障礙。這項特性要求嚴格的超低溫儲存和運輸。這種技術要求導致高昂的基礎設施成本和複雜的物流配送，尤其是在資源匱乏的地區。因此，這些物流障礙限制了mRNA產品的順利商業性化應用，使其主要局限於大型製藥市場，阻礙了其在全球範圍內的進一步擴張。

市場促進因素

推動市場成長的關鍵動力在於策略性地拓展至癌症治療和罕見遺傳疾病領域，這促使該技術超越其在感染疾病預防領域最初的成功。研發人員正在加速開發個人化癌症免疫療法，利用mRNA的可程式設計訓練免疫系統識別新腫瘤特異性抗原，從而有效降低對疫情相關收入的依賴，同時滿足複雜的未滿足醫療需求。這種向新適應症的轉變在行業趨勢中得到了清晰的體現。例如，Moderna於2025年1月宣布，其五款針對癌症、罕見疾病和潛在疫苗的非呼吸系統候選藥物已進入臨床實驗試驗階段，這標誌著該公司正全面進軍這些新興治療領域。

此外，注入公共和私人資本，並輔以策略聯盟，對於克服高昂的研發成本和擴大生產能力至關重要。大型製藥公司正投入大量資源來加強供應鏈，並加速下一代產品的研發，通常透過合資和許可的方式來分擔風險。例如，賽諾菲在2025年5月宣布，計畫在2030年在美國的研發和生產領域投資至少200億美元。同樣，為了體現這些金融聯盟的規模，BioNTech在2025年3月宣布，預計在2025和2026會計年度將從合作夥伴處獲得約5.35億美元的報銷。

市場挑戰

mRNA分子固有的不穩定性是全球mRNA平台市場發展的一大障礙，因此必須採用嚴格的超低溫鍊式儲存和運輸通訊協定。這項要求迫使生產商依賴專門的、資本密集的基礎設施，例如超低溫儲存單元和溫控運輸貨櫃，而這些設施在開發中國家往往供應短缺。因此，建構這些複雜的配送網路的高昂成本極大地限制了mRNA療法的商業性化應用，使其主要局限於擁有成熟醫藥物流動能力的富裕地區。

對複雜低溫運輸系統的依賴阻礙了全球擴張，因為分銷中斷會帶來巨大的財務風險。大量高價值治療藥物在全球價值鏈中流通，更凸顯了這種依賴關係。根據國際航空運輸協會（IATA）預測，到2024年，製藥業將運輸價值1兆美元的貨物，凸顯了溫控生物製藥運輸的巨大經濟效益和基礎設施需求。除非這些物流負擔得到緩解，否則mRNA療法在主要經濟體以外的地區實現公平取得和順利商業性成長方面將繼續面臨挑戰。

市場趨勢

人工智慧和機器學習在序列最佳化領域的融合，透過高精度預測翻譯效率和免疫抗原性，正在革新mRNA療法的設計。透過深度學習演算法分析海量mRNA序列資料集，研發人員可以辨識出最佳的密碼子使用和結構構型，從而在最大限度地提高蛋白質生產的同時，最大限度地降低不穩定性。這種計算策略加速了候選藥物的發現，顯著減少了對重複性濕實驗的依賴，並加快了從概念到臨床試驗的轉化。例如，在2025年10月的AI Day上，InstaDeep展示了其最新的AI模型在識別新型肽靶點方面，準確率提高了10-15%，推理速度提高了50倍，凸顯了計算生物學在提升效率方面的巨大潛力。

同時，環狀RNA（circRNA）技術的進步代表著一種結構上的轉變，旨在克服線性mRNA分子壽命短的缺陷。透過將RNA工程化為共用閉合的環狀結構，這些平台能夠抵抗核酸外切酶的分解，並實現更持久的蛋白質表現。這使得藥物劑量可以降低，毒性風險也隨之降低。這種結構創新在需要持續治療效果的治療領域中尤其重要，例如蛋白質替代療法，將市場拓展到急性疫苗應用之外。 2025年12月，Ohna Therapeutics公司公佈了臨床前數據，顯示其領先的環狀RNA候選藥物在非人靈長類動物中僅以0.1 mg/kg的劑量即可實現強效的免疫細胞清除效果，證明了該平台具有增強療效和延長作用持續時間的潛力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球mRNA平台市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依適應症（自體免疫疾病、癌症、感染疾病、罕見疾病、呼吸系統疾病）
    • 依用途（預防性疫苗、治療性疫苗、治療性疫苗）
    • 依mRNA類型（核苷修飾的mRNA、自擴增mRNA、未修飾的mRNA）
    • 依最終用戶（醫院/診所、製藥公司、研究機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美mRNA平台市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲mRNA平台市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章 亞太地區mRNA平台市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲mRNA平台市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美mRNA平台市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球mRNA平台市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17266

The Global mRNA Platform Market is projected to expand from USD 7.52 Billion in 2025 to USD 9.59 Billion by 2031, reflecting a compound annual growth rate of 4.14%. This sector encompasses technologies that employ messenger RNA to guide host cells in synthesizing specific proteins, enabling disease prevention and treatment through delivery systems like lipid nanoparticles. Key catalysts fueling this growth include the critical need for rapid vaccine development platforms during infectious outbreaks and the massive investment directed toward extending this modality into oncology and rare disease treatments. Highlighting the focus on production, the Alliance for mRNA Medicines reported in 2025 that 49% of surveyed industry organizations pinpointed manufacturing processing efficiency as a primary element for enhancing the global affordability and accessibility of mRNA-based medicines.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.52 Billion
Market Size 2031USD 9.59 Billion
CAGR 2026-20314.14%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Despite these advancements, the market faces a substantial hurdle due to the inherent instability of mRNA molecules, which mandates rigorous ultra-cold chain logistics for both storage and transport. This technical requirement results in elevated infrastructure expenses and complicated distribution logistics, particularly in resource-constrained areas. Consequently, these logistical barriers restrict the seamless commercial adoption of mRNA products, largely confining their availability to major pharmaceutical markets and impeding broader global expansion.

Market Driver

A pivotal growth engine for the market is the strategic expansion into oncology and rare genetic disorders, propelling the technology beyond its initial triumphs in infectious disease prevention. Developers are increasingly utilizing the programmability of mRNA to engineer personalized cancer immunotherapies that train the immune system to detect tumor-specific neoantigens, effectively reducing dependence on pandemic-related revenue while addressing complex, unmet medical needs. This shift toward new indications is evident in industry activities; for instance, Moderna reported in January 2025 that it had advanced five non-respiratory candidates into pivotal studies covering cancer, rare diseases, and latent vaccines, signaling a robust pivot toward these emerging therapeutic areas.

Additionally, the infusion of public and private capital, bolstered by strategic alliances, is crucial for surmounting steep development costs and scaling manufacturing capacities. Leading pharmaceutical companies are dedicating massive resources to fortify supply chains and expedite R&D for next-generation assets, often utilizing joint ventures and licensing deals to share risk. To illustrate this commitment, Sanofi announced in May 2025 a plan to invest at least $20 billion in U.S.-based research, development, and manufacturing through 2030. Similarly, highlighting the magnitude of these financial partnerships, BioNTech projected in March 2025 that it would receive approximately $535 million in reimbursements from its collaboration partner over the 2025 and 2026 fiscal years.

Market Challenge

The fundamental instability of the mRNA molecule acts as a formidable obstacle to the Global mRNA Platform Market, necessitating strict ultra-cold chain protocols for storage and transportation. This requirement compels manufacturers to depend on specialized, capital-intensive infrastructure, such as deep-freeze storage units and temperature-controlled shipping containers, which are frequently scarce in developing nations. As a result, the exorbitant costs involved in building these intricate distribution networks severely restrict the commercial scope of mRNA therapeutics, effectively limiting their primary adoption to affluent regions that possess established pharmaceutical logistics capabilities.

Reliance on such sophisticated cold chain systems hinders global expansion, as the financial risks linked to distribution failures are prohibitive. The scale of this dependency is underscored by the immense volume of high-value treatments traversing the global supply chain; according to the International Air Transport Association (IATA), the pharmaceutical industry transported over US$ 1 trillion worth of cargo in 2024, emphasizing the massive economic stakes and infrastructure requirements for shipping temperature-sensitive biologics. Unless these logistical burdens are alleviated, the mRNA modality will continue to struggle with achieving equitable accessibility and seamless commercial growth outside of major economic centers.

Market Trends

The integration of AI and Machine Learning for sequence optimization is transforming the design of mRNA therapeutics by predicting translation efficiency and immunogenicity with high precision. By employing deep learning algorithms to examine extensive datasets of mRNA sequences, developers can identify optimal codon usage and structural configurations that maximize protein output while minimizing instability. This computational strategy accelerates candidate discovery, significantly lowering the dependence on iterative wet-lab experimentation and speeding up the move from concept to clinical trials. For example, during its 'AI Day' in October 2025, InstaDeep demonstrated that its newest AI model offered a 10-15% improvement in accuracy and 50-fold faster inference speeds for identifying novel peptide targets, highlighting the efficiency gains provided by computational biology.

Concurrently, the advancement of Circular RNA (circRNA) technologies marks a structural shift designed to overcome the transient nature of linear mRNA molecules. By engineering RNA into a covalently closed loop, these platforms resist degradation by exonucleases, enabling more durable protein expression and permitting lower dosing regimens that decrease toxicity risks. This architectural innovation is especially critical for therapeutic areas requiring sustained treatment effects, such as protein replacement therapies, pushing the market beyond acute vaccine applications. In December 2025, Orna Therapeutics presented preclinical data indicating that its lead circular RNA candidate achieved robust immune cell depletion in non-human primates at doses as low as 0.1 mg/kg, validating the platform's potential for enhanced potency and extended duration.

Key Market Players

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

Report Scope

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication

  • Autoimmune Diseases
  • Cancer
  • Infectious Diseases
  • Rare Diseases
  • Respiratory Diseases

mRNA Platform Market, By Usability

  • Prophylactic Vaccines
  • Therapeutic Drugs
  • Therapeutic Vaccines

mRNA Platform Market, By mRNA Type

  • Nucleoside-Modified mRNA
  • Self-Amplifying mRNA
  • Unmodified mRNA

mRNA Platform Market, By End User

  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Organization

mRNA Platform Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
    • 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
    • 5.2.3. By mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA)
    • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America mRNA Platform Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Usability
    • 6.2.3. By mRNA Type
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States mRNA Platform Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Usability
        • 6.3.1.2.3. By mRNA Type
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada mRNA Platform Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Usability
        • 6.3.2.2.3. By mRNA Type
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico mRNA Platform Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Usability
        • 6.3.3.2.3. By mRNA Type
        • 6.3.3.2.4. By End User

7. Europe mRNA Platform Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Usability
    • 7.2.3. By mRNA Type
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany mRNA Platform Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Usability
        • 7.3.1.2.3. By mRNA Type
        • 7.3.1.2.4. By End User
    • 7.3.2. France mRNA Platform Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Usability
        • 7.3.2.2.3. By mRNA Type
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom mRNA Platform Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Usability
        • 7.3.3.2.3. By mRNA Type
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy mRNA Platform Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Usability
        • 7.3.4.2.3. By mRNA Type
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain mRNA Platform Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Usability
        • 7.3.5.2.3. By mRNA Type
        • 7.3.5.2.4. By End User

8. Asia Pacific mRNA Platform Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Usability
    • 8.2.3. By mRNA Type
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China mRNA Platform Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Usability
        • 8.3.1.2.3. By mRNA Type
        • 8.3.1.2.4. By End User
    • 8.3.2. India mRNA Platform Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Usability
        • 8.3.2.2.3. By mRNA Type
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan mRNA Platform Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Usability
        • 8.3.3.2.3. By mRNA Type
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea mRNA Platform Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Usability
        • 8.3.4.2.3. By mRNA Type
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia mRNA Platform Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Usability
        • 8.3.5.2.3. By mRNA Type
        • 8.3.5.2.4. By End User

9. Middle East & Africa mRNA Platform Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Usability
    • 9.2.3. By mRNA Type
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia mRNA Platform Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Usability
        • 9.3.1.2.3. By mRNA Type
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE mRNA Platform Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Usability
        • 9.3.2.2.3. By mRNA Type
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa mRNA Platform Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Usability
        • 9.3.3.2.3. By mRNA Type
        • 9.3.3.2.4. By End User

10. South America mRNA Platform Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Usability
    • 10.2.3. By mRNA Type
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil mRNA Platform Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Usability
        • 10.3.1.2.3. By mRNA Type
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia mRNA Platform Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Usability
        • 10.3.2.2.3. By mRNA Type
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina mRNA Platform Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Usability
        • 10.3.3.2.3. By mRNA Type
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Asuragen, Inc.
  • 15.3. Catalent Pharma Solutions
  • 15.4. Arcturus Therapeutics, Inc.
  • 15.5. BioNTech AG
  • 15.6. CRISPR Therapeutics Inc.
  • 15.7. AKESOgen, Inc.
  • 15.8. baseclick GmbH
  • 15.9. Accent Therapeutics Inc.
  • 15.10. Accanis Biotech F&E GmbH & Co KG

16. Strategic Recommendations

17. About Us & Disclaimer